BG MidCap Daily – Bryan, Garnier & Co.

Today's comment(s)

Bureau Veritas (NEUTRAL, Fair Value EUR20 vs. EUR21)

Feed back conference call: No significant recovery expected in FY 2016. FV reduced.

Following Q3 revenue, management has lowered its FY 2016 guidance and is now expecting "slightly" negative IfI revenue growth (i.e. first negative FY number since the IPO) with adjusted operating margin of 16-16.5% compared with 16.5-17% previously and 16.7% last year. We have lowered our estimates for IfI revenue growth from 0.9% to -0.3% (consensus was at 0.4%) maintaining our adjusted operating margin at 16.3% (consensus was at 16.6%). Based on our new numbers, our FV moves to EUR20 vs. EUR21 based on a DCF and historical multiple EV/EBIT on FY+3. Too early to revisit the stock.

Bureau Veritas (NEUTRAL, Fair Value EUR20 vs. EUR21)

Feed back conference call: No significant recovery expected in FY 2016. FV reduced.

Following Q3 revenue, management has lowered its FY 2016 guidance and is now expecting "slightly" negative IfI revenue growth (i.e. first negative FY number since the IPO) with adjusted operating margin of 16-16.5% compared with 16.5-17% previously and 16.7% last year. We have lowered our estimates for IfI revenue growth from 0.9% to -0.3% (consensus was at 0.4%) maintaining our adjusted operating margin at 16.3% (consensus was at 16.6%). Based on our new numbers, our FV moves to EUR20 vs. EUR21 based on a DCF and historical multiple EV/EBIT on FY+3. Too early to revisit the stock.

Burberry (NEUTRAL, Fair Value 1260p vs. 1200p)

GBP weakness helps!

H1 sales were globally in line with expectations with a retail sales rebound in Q2, mainly driven by Europe and particularly by the UK. Given recent GBP weakness, we have adjusted our FY 2016 expectations (revising up EBIT by 5%). As such, we have lifted our FV from p1,200 to p1,250. Nevertheless, we keep our Neutral recommendation.

Gemalto (NEUTRAL, Fair Value EUR60 vs. EUR62)

We have cut our estimates again to feel more comfortable for the next few years

We were not comfortable with our estimates prior to the Q3 revenue release (on 28th October, before trading), both for H2 2016e and FY 2017e. We have therefore reduced our 2016-18e EPS sequence by 6% on average (-6.4% in 2016e, -6.1% in 2017e and -5.3% in 2018e). We maintain our Neutral recommendation and have lowered our FV from EUR62 to EUR60. The stock is often a "value trap" and we advise investors to remain cautious as we expect the company to warn sooner or later.

Metro AG (SELL, Fair Value EUR26)

Q4 trading statement (first take): topline remains weak

The negative and salient point of the publication was the poor performance at MMS (-2.0% LFL vs +0.4%e), notably penalised by difficult momentum at Redcoon. Even if management confirmed the FY EBIT BFI guidance, we continue to consider that topline performances remain weak (flat LFL in Q4) and do not allow talk of a commercial recovery, not to mention the credit situation, which remains a source of concern going forward. Sell maintained at this stage.

Rémy Cointreau (BUY-Top Picks, Fair Value EUR84)

A good set of results

The group reported a good set of results yesterday. The United States continued to grow strongly and China confirmed its improvement. Value depletions in the country were up mid single digit in

Q2, in line with Q1. However this has triggered no upwards revisions to estimates. We maintain our Buy recommendation and our Fair Value of EUR84.

Casino Guichard (BUY, Fair Value EUR57)

Via Varejo

Yesterday, the Casino share price suddenly jumped 2% as Steinhoff was reported (source: Globo / the information was obviously denied) to be in talks to buy the Klein family stake in Via Varejo (Casino's electro-domestic subsidiary in Brazil / El 14%). Beyond the modest impact on Casino's SOTP (EUR0.65), the message is the key factor. Casino had to mourn the valuation of Via Varejo (which, in 2014, was valued three times its current market cap). Today, we believe that Casino is ready to sell the asset.

AccorHotels (BUY, Fair Value EUR42)

Conference call Q3 revenue: stronger than anticipated. FY guidance narrowed as expected.

Q3 numbers were higher than expected with total revenue reaching EUR1.538bn (consensus at EUR1.502bn and BG at EUR1.509bn) up 3% in reported terms with Ifl revenue growth of 1.8% while the consensus was forecasting 0.4% (BG at 1.3%). Q3 performance was even more remarkable given summer season headwinds especially in France and Belgium. After 9m, management narrowed its FY guidance as expected to EUR670m-EUR690m vs. EUR670m-EUR720m previously (consensus at EUR675m) reflecting uncertainties in France. Positive.

Brief comments

Galapagos (BUY, Fair Value EUR64)

Detailed GED-0301 results... filgotinib appears better in a more difficult to treat population

Latest Recommendation Changes

SOBI : Haemophilia: « Stemming the bleed » TEMENOS GROUP : Large deal with a major European bank InterContinental Hotels : Top picks: ...and the winner is Melia. PLASTIC OMNIUM : Innovation: the only way to stand out! HELLA : Innovation: the only way to stand out! FAURECIA : Innovation: the only way to stand out!

Latest Fair value changes

BUREAU VERITAS : Feed back conference call: No significant recovery expected in FY 2016. FV reduced. GEMALTO : We have cut our estimates again to feel more comfortable for the next few years SOBI : Haemophilia: « Stemming the bleed » TEMENOS GROUP : Success breeds success

Stocks Factor to watch today on Mid & Small :

EDENRED: THREE-YEAR STRATEGIC PLAN; SEEKS ANNUAL COMP OPERATING REV GROWTH OF OVER 7% AND COMP OPERATING EBIT GROWTH OF OVER 9%; AIMS TO PAY DIVS AT LEAST 80% OF GROUP'S NET PROFIT

RALLYE: LAUNCHES OFFERING OF NON-DILUTIVE CASH-SETTLED BONDS DUE; SELLS EU200M BONDS DUE FEB. 2022; BONDS EXCHANGEABLE INTO CASINO SHRS

Rating & TP Changes

+REMY COINTREAU: TP raised to €69 vs. 65, SELL @Berenberg
+REMY COINTREAU: TP raised to €92 vs. 88, BUY @HSBC
+REMY COINTREAU: TP raised to €82 vs. 80, HOLD @Jefferies
+IPSEN : fv raised to €72 vs. 67, BUY @Bryan Garnier

-BUREAU VERITAS : TP cut to €17 vs. 18.2, UNDERWEIGHT @JPM -BUREAU VERITAS : TP cut to €18.5 vs. 19, EQUAL WEIGHT@Barlcays -BUREAU VERITAS : TP cut to €20 vs. 21, NEUTRAL @Bryan Garnier

Technical analysis

	Last	%var	% var
	close	1D	31/12/15
FRANCE CAC MID & SMALL	11268.44	+0.79%	+1.94%
STOXX EUROPE TM MID	505.404	+1.46%	-6.10%

*BG Coverage

Highest YTD : ABC ARBITRAGE (BITI.PA), ALTAMIR (ALMP.PA), ATEME (ATEME.PA), ENCRES DUBUIT (EDUB.PA), GEVELOT (ALGEV.PA), THEOLIA (FTRN.PA)

Lowest YTD : ERYTECH PHARMA* (ERYP.PA), LES HOTELS BAVEREZ (ALLHB.PA), POXEL (POXEL.PA), TXCELL (TXCL.PA), VIRBAC* (VIRB.PA)

Excess volume/1D : ABC ARBITRAGE (BITI.PA), AMPLITUDE SURGICAL (AMPLI.PA), APRIL (APRL.PA), ATEME (ATEME.PA), <u>BIC*</u> (BICP.PA), <u>BIOMERIEUX*</u> (BIOX.PA), BONDUELLE (BOND.PA), CARLSBERG 'A' (CARLa.CO), CATANA GROUP (CATGR.PA), CBO TERRITORIA (CBOT.PA), CR.AGRICOLE MORBIHAN (CMO.PA), CRCAM ATLANTIQUE VENDEE (CALCI.PA), CRCAM ILLE-VIL.CCI (CIV.PA), CRCAM NORD DE FRANCE CCI (CADNI.PA), CREDIT AGR.TOURAINE (CRTO.PA), DELTA PLUS GROUP (DLTG.PA), <u>DISTRIBUIDORA INTNAC.DE ALIMENTACION*</u> (DIDA.MC), ENCRES DUBUIT (EDUB.PA), <u>ERYTECH PHARMA*</u> (ERYP.PA), FLEURY MICHON (FLMI.PA), GEVELOT (ALGEV.PA), GRIFOLS CLASS 'B' SHARE (GRLSbn.MC), HEURTEY PETROCHEM SUSP - 10/10/16 (ALHPC.PA), HIGH CO (HIGH.PA), ICADE (ICAD.PA), IDI (IDVP.PA), <u>IMERYS*</u> (IMTP.PA), INTL.PLTNS.D HEVEAS (SIPH.PA), LANSON-BCC (LAN.PA), LDLC.COM (LDCO.PA), MEDIAN TECHNOLOGIES (ALMDT.PA), PIERRE & VACANCES (PVAC.PA), POXEL (POXEL.PA), VELCAN (ALVEL.PA), <u>VICAT*</u> (VCTP.PA), <u>VOLTALIA*</u> (VLTSA.PA), VOYAGEURS DU MONDE (ALVDM.PA)

⁽¹⁾Compare the previous day trading volume to last month average volume traded

Calendar

Company name

Temenos Group AG(TEMN SW)

Edenred(EDEN FP)

- Worldline SA/France(WLN FP)
- ٠

Date

19/10/16

type Earnings result : Shareholders meeting

4